Drug Type Small molecule drug |
Synonyms Levodroproizine, Levodropropizine Buccal, DF-526 + [11] |
Target- |
Mechanism Neuropeptides modulators(Neuropeptides modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date IT (01 Jan 1988), |
Regulation- |
Molecular FormulaC13H20N2O2 |
InChIKeyPTVWPYVOOKLBCG-ZDUSSCGKSA-N |
CAS Registry99291-25-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Levodropropizine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cough | IT | 01 Jan 1988 |
Phase 3 | 184 | (Levopront® Syrup 30 mg/5 ml) | nyipcziigd(dxhvcojdyu): Difference in rates Levopront®-Libexin® = 5.81 (97.5% CI) View more | - | 15 Apr 2024 | ||
(Libexin® 100 mg Tablets) |